Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities
The utilization of Androgen Deprivation Therapy (ADT) in conjunction with Stereotactic Body Radiotherapy (SBRT) and Brachytherapy (BT) boost in prostate cancer treatment is a subject of ongoing debate and evolving clinical practice. While contemporary trends lean towards underutilizing ADT with thes...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Clinical and Translational Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630824000107 |
| _version_ | 1797272434141822976 |
|---|---|
| author | A. Gomez-Iturriaga D. Büchser F. Lopez-Campos X. Maldonado |
| author_facet | A. Gomez-Iturriaga D. Büchser F. Lopez-Campos X. Maldonado |
| author_sort | A. Gomez-Iturriaga |
| collection | DOAJ |
| description | The utilization of Androgen Deprivation Therapy (ADT) in conjunction with Stereotactic Body Radiotherapy (SBRT) and Brachytherapy (BT) boost in prostate cancer treatment is a subject of ongoing debate and evolving clinical practice. While contemporary trends lean towards underutilizing ADT with these modalities, existing evidence suggests that its omission may lead to potentially inferior oncologic outcomes. Recommendations for ADT use should be patient-centric, considering individual risk profiles and comorbidities, with a focus on achieving optimal oncologic outcomes while minimizing potential side effects.Ongoing clinical trials, such as PACE-C, SPA, SHIP 0804, and SHIP 36B, are anticipated to provide valuable insights into the optimal use and duration of ADT in both SBRT and BT settings. Until new evidence emerges, it is recommended to initiate ADT for unfavorable intermediate-risk and high-risk prostate cancer patients undergoing radiotherapy, with a minimum duration of 6 months for unfavorable intermediate-risk patients and at least 12 months for those with high-risk characteristics. The decision to incorporate ADT into these radiation therapy modalities should be individualized, acknowledging the unique needs of each patient and emphasizing a tailored approach to achieve the best possible oncologic outcomes. |
| first_indexed | 2024-03-07T14:29:18Z |
| format | Article |
| id | doaj.art-a453838328104490a4f2932fff6e1f6d |
| institution | Directory Open Access Journal |
| issn | 2405-6308 |
| language | English |
| last_indexed | 2024-03-07T14:29:18Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical and Translational Radiation Oncology |
| spelling | doaj.art-a453838328104490a4f2932fff6e1f6d2024-03-06T05:27:50ZengElsevierClinical and Translational Radiation Oncology2405-63082024-03-0145100733Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalitiesA. Gomez-Iturriaga0D. Büchser1F. Lopez-Campos2X. Maldonado3Hospital Universitario Cruces/ Biobizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain; Department of Surgery and Radiology and Physical Medicine, University of the Basque Country UPV/EHU, Spain; Corresponding author at: Department of Radiation Oncology, Hospital Universitario Cruces, Plaza Cruces Gurutzeta 12. 48903, Barakaldo, Spain.Hospital Universitario Cruces/ Biobizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain; Department of Surgery and Radiology and Physical Medicine, University of the Basque Country UPV/EHU, SpainHospital Universitario Ramon y Cajal, Radiation Oncology, Madrid, SpainHospital Vall d́Hebron, Radiation Oncology, Barcelona, SpainThe utilization of Androgen Deprivation Therapy (ADT) in conjunction with Stereotactic Body Radiotherapy (SBRT) and Brachytherapy (BT) boost in prostate cancer treatment is a subject of ongoing debate and evolving clinical practice. While contemporary trends lean towards underutilizing ADT with these modalities, existing evidence suggests that its omission may lead to potentially inferior oncologic outcomes. Recommendations for ADT use should be patient-centric, considering individual risk profiles and comorbidities, with a focus on achieving optimal oncologic outcomes while minimizing potential side effects.Ongoing clinical trials, such as PACE-C, SPA, SHIP 0804, and SHIP 36B, are anticipated to provide valuable insights into the optimal use and duration of ADT in both SBRT and BT settings. Until new evidence emerges, it is recommended to initiate ADT for unfavorable intermediate-risk and high-risk prostate cancer patients undergoing radiotherapy, with a minimum duration of 6 months for unfavorable intermediate-risk patients and at least 12 months for those with high-risk characteristics. The decision to incorporate ADT into these radiation therapy modalities should be individualized, acknowledging the unique needs of each patient and emphasizing a tailored approach to achieve the best possible oncologic outcomes.http://www.sciencedirect.com/science/article/pii/S2405630824000107Prostate cancerSBRTBrachytherapyAndrogen DeprivationReview |
| spellingShingle | A. Gomez-Iturriaga D. Büchser F. Lopez-Campos X. Maldonado Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities Clinical and Translational Radiation Oncology Prostate cancer SBRT Brachytherapy Androgen Deprivation Review |
| title | Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities |
| title_full | Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities |
| title_fullStr | Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities |
| title_full_unstemmed | Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities |
| title_short | Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities |
| title_sort | enhancing androgen deprivation therapy adt integration in prostate cancer insights for stereotactic body radiotherapy sbrt and brachytherapy modalities |
| topic | Prostate cancer SBRT Brachytherapy Androgen Deprivation Review |
| url | http://www.sciencedirect.com/science/article/pii/S2405630824000107 |
| work_keys_str_mv | AT agomeziturriaga enhancingandrogendeprivationtherapyadtintegrationinprostatecancerinsightsforstereotacticbodyradiotherapysbrtandbrachytherapymodalities AT dbuchser enhancingandrogendeprivationtherapyadtintegrationinprostatecancerinsightsforstereotacticbodyradiotherapysbrtandbrachytherapymodalities AT flopezcampos enhancingandrogendeprivationtherapyadtintegrationinprostatecancerinsightsforstereotacticbodyradiotherapysbrtandbrachytherapymodalities AT xmaldonado enhancingandrogendeprivationtherapyadtintegrationinprostatecancerinsightsforstereotacticbodyradiotherapysbrtandbrachytherapymodalities |